Medication Reference Card — Opioid Analgesic Dependence

Buprenorphine Transdermal Patch

Norspan® (5, 10, 20 mcg/hr) · Weekly patch · TGA-approved for chronic pain · S8 Authority Required

Dr Basanth Kenchaiah
FRANZCP · MBBS · DPM · DNB (Psychiatry) · Cert. Addiction Psych. Addiction Psychiatrist v1.0 · May 2026

Audience Clinicians

Purpose Prescribing reference for transdermal buprenorphine (Norspan®) in opioid analgesic dependence and micro-induction.

Key messages

Low-dose transdermal delivery — useful for micro-induction onto buprenorphine from full agonist opioids
Norspan® 5, 10, 20 mcg/hr weekly patch; TGA-approved for chronic non-cancer pain; S8 authority required
Not equivalent to sublingual OUD dosing; use Bernese/BRIXM protocol for overlap strategy with full agonists

For Clinicians

Mechanism & Pharmacokinetic Rationale

Same partial mu-opioid agonist pharmacology as sublingual buprenorphine — high receptor affinity, slow dissociation, ceiling for respiratory depression. Transdermal delivery achieves steady-state plasma levels without peaks/troughs, reaching therapeutic concentration over 12–24 hours after first application. The key clinical advantage: at 5 mcg/hour (Norspan 5), the daily buprenorphine absorption is approximately 120 mcg/day — well below the threshold required to displace sufficient full agonist opioid to precipitate withdrawal. This allows buprenorphine to begin occupying mu-opioid receptors incrementally, forming the pharmacokinetic basis for its use in micro-induction (Bernese method).

Available Formulations (Australia)

Patch strength	Release rate	~Daily absorption	~SL buprenorphine equivalent
Norspan® 5	5 mcg/hour	~120 mcg/day	~0.12 mg/day (micro-dose)
Norspan® 10	10 mcg/hour	~240 mcg/day	~0.25 mg/day
Norspan® 20	20 mcg/hour	~480 mcg/day	~0.5 mg/day

Apply to upper outer arm, chest, or back. Rotate sites weekly. Avoid heat (electric blankets, hot baths) — increases absorption unpredictably.

Clinical Scenarios & Dosing

Scenario A — Low-dose opioid dependence (codeine / tramadol)

Apply Norspan 5 patch while still taking current opioid
Continue current opioid for days 1–3 (patch reaching steady-state)
Reduce current opioid by 25–50% on day 3–5 as tolerated
By day 5–7: cease current opioid; either continue patch and taper, or transition to SL buprenorphine/naloxone (COWS-guided — usually straightforward at this low opioid burden)
Norspan 10 may suffice as maintenance for very low-level dependence

Scenario B — Bernese micro-induction (moderate–high dose opioid analgesics)

Day 1: Apply Norspan 5 patch — patient remains on current opioid (e.g. oxycodone, fentanyl patch, methadone)
Day 2: Add sublingual buprenorphine 0.2–0.4 mg; continue full agonist at usual dose
Days 3–5: Increase SL buprenorphine by 0.4–2 mg/day per Bernese protocol
Day 5–7: Remove patch once SL buprenorphine reaches 6–8 mg/day
Titrate to SL maintenance (8–24 mg/day); cease full agonist over this period

Evidence

The patch-specific use in addiction is supported by pharmacokinetic modelling, expert consensus, and case series rather than large RCTs — this should be disclosed to patients. The Bernese method itself (Hämmig et al. 2016) was validated with sublingual microdoses; patches are a clinically logical extension given their steady-state kinetics and lower bioavailability. The NDARC Australian guidelines and emerging micro-induction literature (Weimer et al. 2020, Breen et al. 2023) support low-dose induction strategies. For the patch as maintenance in codeine dependence: clinical experience and pharmacokinetic data support adequacy of Norspan 5–10 for opioid receptor stabilisation at this dose range; formal RCT data in this specific population are lacking.

Cautions & Practical Points

Off-label for addiction — requires specialist, MATOD-authorised GP, or hospital authority in most Australian states
Heat exposure (electric blankets, fever, hot baths) significantly increases transdermal absorption — counsel patients; potential toxicity risk
Disposal: used patches retain significant residual buprenorphine — fold sticky sides together, return to pharmacy or dispose safely; keep away from children and pets
Skin reactions: rotate application sites every 7 days; avoid irritated or broken skin
At 5–10 mcg/hour the analgesic effect is modest — do not mistake for adequate pain treatment in opioid-tolerant patients with moderate-severe pain
Respiratory depression risk: monitor carefully if continuing full agonist opioids concurrently during transition — the combination is intentional but requires clinical oversight
No naloxone component (unlike Suboxone) — injection misuse would be active; lower misuse potential than SL given transdermal route but not zero
Renal and hepatic impairment: no dose adjustment required for mild-moderate disease; use with caution in severe hepatic impairment